The market is expected to consolidate with range-bound trading after the sharp correction. Below are some short-term trading ...
Danish pharmaceutical major Novo Nordisk has joined hands with Indian drugmaker Emcure Pharmaceuticals to expand the availability of its injectable obesity drug, semaglutide, across India. The ...
Emcure Pharmaceuticals saw its shares reach the upper circuit limit of 10 percent on Friday, May 23, 2025, continuing a rally for the third day in a row with an impressive overall gain of nearly 20 ...
The expiry of the shareholder lock in, however, does not necessarily imply that all these shares will be sold in the open ...
Emcure Pharmaceuticals has witnessed a strong bullish breakout from its consolidation phase, supported by a clear surge in ...
Wakefit Innovations, ICICI Prudential AMC, Canara HSBC Life Insurance and Emcure Pharmaceuticals are among the key names set ...
While Namita Thapar has worked with her father’s company, Emcure Pharmaceuticals, for the last 19 years, in 2024, she stepped ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
(Reuters) -Novo Nordisk has partnered with India's Emcure Pharmaceuticals to exclusively distribute and market its weight-loss drug under a new brand in the country, the companies said on Monday.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback